Karl-Erik Andersson to Drug Therapy, Combination
This is a "connection" page, showing publications Karl-Erik Andersson has written about Drug Therapy, Combination.
Connection Strength
0.478
-
Andersson KE. Drug therapy of overactive bladder--what is coming next? Korean J Urol. 2015 Oct; 56(10):673-9.
Score: 0.109
-
Andersson KE. The use of pharmacotherapy for male patients with urgency and stress incontinence. Curr Opin Urol. 2014 Nov; 24(6):571-7.
Score: 0.102
-
Füllhase C, Soler R, Gratzke C, Brodsky M, Christ GJ, Andersson KE. Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction. J Urol. 2010 Aug; 184(2):783-9.
Score: 0.075
-
Füllhase C, Soler R, Gratzke C, Brodsky M, Christ GJ, Andersson KE. Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. BJU Int. 2010 Jul; 106(2):287-93.
Score: 0.072
-
Andersson KE. How many drugs for LUTS due to BPH are too many? J Urol. 2008 Sep; 180(3):811-2.
Score: 0.066
-
Serati M, Andersson KE, Dmochowski R, Agrò EF, Heesakkers J, Iacovelli V, Novara G, Khullar V, Chapple C. Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. Eur Urol. 2019 01; 75(1):129-168.
Score: 0.033
-
Streng T, Andersson KE, Hedlund P, Gratzke C, Baroni E, D'Ambrosio D, Benigni F. Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction. BJU Int. 2012 Jul; 110(2 Pt 2):E125-31.
Score: 0.021